

2010 ITMAT INTERNATIONAL SYMPOSIUM

Interesting Times: The Academic Contribution to Development of Novel Therapeutics in an Era of Reform

University of Pennsylvania School of Medicine
Biomedical Research Building II/III
Auditorium/Lobby
421 Curie Boulevard, Philadelphia, PA 19104
October 26-27, 2010

Tuesday October 26th 2010

8:00 Registration: BRB Lobby

9:15 Welcome

Arthur H. Rubenstein, MBBCh, Executive Vice President, University of Pennsylvania for the Health System, Dean, School of Medicine

9:30 Session 1: Academic Health Systems in an Era of Reform - I

Chairs: Daniel J. Rader, MD, Associate Director of ITMAT, University of Pennsylvania and Pamela B. Davis, MD, PhD, Dean, School of Medicine, Case Western Reserve University

The Complexity of Drug Development--New Models for the Future

Dennis A. Ausiello, MD, Jackson Professor of Clinical Medicine at Harvard Medical School, Chief of Medicine at Massachusetts General Hospital (MGH), and Chief Scientific Officer of Partners Healthcare

The Academic Mission in a Complex Health System

Ralph W. Muller, Chief Executive Officer of the University of Pennsylvania Health System

Building a Robust Research Commons: Enhancing the Precompetitive Environment

Tania Bubela, PhD, LLB, School of Public Health, University of Alberta

11:15 Coffee: BRB Lobby

11:45 Academic Health Systems in an Era of Reform – II

Chairs: Lisa Guay-Woodford, MD, Director, University of Alabama Center for Clinical and Translational Science and Rory Collins, FRCP FMed Sci, Professor of Medicine & Epidemiology, University of Oxford

Rational Rationing and the Role of Research

Professor Sir Michael Rawlins, MD, Chairman of the National Institute of Health and Clinical Excellence

Academic Engagement by the FDA
Margaret A. Hamburg, MD, FDA Commissioner

1:00 Lunch: BRB Lobby

2:00 Session 2: Infrastructure for Translational Research and Drug Development
Chairs: Etta D. Pisano, MD, Dean, Medical University of South Carolina College of Medicine and C. Thomas Caskey, MD, FACP, Managing Director, Cogene Ventures

The Cures Acceleration Network and Therapeutics at NIH
Francis S. Collins, MD, PhD, Director, National Institutes of Health

Genomic Exploitation
Lon Cardon, PhD., Senior Vice President Quantitative Sciences, GlaxoSmithKline

The Academic Contribution to Drug Development
Roger M. Perlmutter, MD, PhD, EVP, Research and Development, Amgen

Bridging the Valley of Death in Academic Drug Discovery
Dennis C. Liotta, PhD, Director, Emory Institute for Drug Discovery

6:00 Reception and Dinner **The College of Physicians of Philadelphia,
19 South 22nd Street, Philadelphia**
Buses will depart from BRB entrance at 5:40 PM
**(Speakers and chairs may take a shuttle bus from the Hilton Inn at
Penn, 3600 Sansom Street, departing at 5:40 PM)**

Wednesday October 27th 2010

8:15 Registration: BRB Lobby

9:00 Session 3: Models and Opportunities
**Thomas A. Baillie, PhD, DSc, Dean, School of Pharmacy, University of Washington
and Harvey Rubin, M.D., PhD, Department of Medicine, University of Pennsylvania**

Developing Drugs for Neglected Diseases: Lessons from the Nonprofit Sector
Richard Chin, MD, OneWorld Health

The Innovative Medicines Initiative, a European public-private partnership in healthcare
Michel Goldman, MD, PhD, Executive Director, Innovative Medicines Initiative, Brussels, Belgium

PROOF of the Pudding in Canada

Bruce M. McManus, MD, PhD, Professor, Department of Pathology and Laboratory Medicine, UBC, Director, NCE CECR Center of Excellence for the Prevention of Organ failure (PROOF Centre)

10:45 Coffee: BRB Lobby

11:15 Session 4: Emerging Opportunities – I

Alastair J.J. Wood, MB, ChB, FRCP, Managing Director, Symphony Capital LLC and Julianne L. Imperato-McGinley, MD, Associate Dean, Translational Research and Education Program Director, Clinical and Translational Science Center Abby Rockefeller Mauzé Distinguished Professor of Endocrinology in Medicine Chief, Division of Endocrinology Weill Cornell Medical College

How Useful is Pharmacogenetics?

Russ B. Altman, MD, PhD, Stanford University

Vaccines in the Modern Era: New Paradigms to Address Unmet Needs

Gary J. Nabel, MD, PhD, Director, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH

12:30 Lunch

1:30 Session 5: Emerging Opportunities – II

Chairs: Susan M. Blaney, MD, Professor of Pediatrics, Texas Children’s Cancer Center and Baylor College of Medicine, and Desmond Fitzgerald, MD, Vice President for Research, University College Dublin

Challenges to Drug Development in Academia

Charles L. Sawyers, MD. , Chair, Human Oncology and Pathogenesis Program; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute

The ReBirth of Gene Therapy

Jean Bennett, MD, PhD, University of Pennsylvania

Adaptive Clinical Trials: A New Paradigm in Drug Development

Donald A. Berry, Ph.D., MD Anderson Cancer Center

3:15 Coffee

3:45 Session 6: Emerging Opportunities - III

Chairs: John B. Hogenesch, PhD, Associate Director, Penn Genomics Frontiers Institute. University of Pennsylvania and Griffin Weber, MD, PhD, Chief Technology Officer, Harvard Medical School

Structural Interactomics and Drug Development

Professor Sir Tom Blundell FRS, FMedSci, Department of Biochemistry, University of Cambridge

Systems Genomics and Drug Discovery

Eric E. Schadt, PhD, Chief Scientific Officer, Pacific Biosciences, SAGE Biosystems

Conclusion

*Garret A. FitzGerald, MD, Chair Department of Pharmacology,
Director, ITMAT, University of Pennsylvania School of Medicine*

Funding for this conference was made possible in part by 1 R13 RR026129-02 from the National Center for Research Resources. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.



NHS
*National Institute for
Health Research*

